Johnson & Johnson Income Taxes 2012-2026 | JNJ
Johnson & Johnson annual/quarterly income taxes history and growth rate from 2012 to 2026. Income taxes can be defined as the total amount of income tax expense for the given period.
- Johnson & Johnson income taxes for the quarter ending March 31, 2026 were $755M, a 71.31% decline year-over-year.
- Johnson & Johnson income taxes for the twelve months ending March 31, 2026 were $3.900B, a 18.65% decline year-over-year.
- Johnson & Johnson annual income taxes for 2025 were $5.777B, a 120.41% increase from 2024.
- Johnson & Johnson annual income taxes for 2024 were $2.621B, a 50.98% increase from 2023.
- Johnson & Johnson annual income taxes for 2023 were $1.736B, a 41.92% decline from 2022.
|
Johnson & Johnson Annual Income Taxes (Millions of US $) |
|
|---|---|
| 2025 | $5,777 |
| 2024 | $2,621 |
| 2023 | $1,736 |
| 2022 | $2,989 |
| 2021 | $1,377 |
| 2020 | $1,783 |
| 2019 | $2,209 |
| 2018 | $2,702 |
| 2017 | $16,373 |
| 2016 | $3,263 |
| 2015 | $3,787 |
| 2014 | $4,240 |
| 2013 | $1,640 |
| 2012 | $3,261 |
| 2011 | $2,689 |
|
Johnson & Johnson Quarterly Income Taxes (Millions of US $) |
|
|---|---|
| 2026-03-31 | $755 |
| 2025-12-31 | $-150 |
| 2025-09-30 | $2,341 |
| 2025-06-30 | $954 |
| 2025-03-31 | $2,632 |
| 2024-12-31 | $456 |
| 2024-09-30 | $644 |
| 2024-06-30 | $1,062 |
| 2024-03-31 | $459 |
| 2023-12-31 | $694 |
| 2023-09-30 | $908 |
| 2023-06-30 | $930 |
| 2023-03-31 | $-796 |
| 2022-12-31 | $388 |
| 2022-09-30 | $862 |
| 2022-06-30 | $1,026 |
| 2022-03-31 | $713 |
| 2021-12-31 | $-421 |
| 2021-09-30 | $182 |
| 2021-06-30 | $384 |
| 2021-03-31 | $1,232 |
| 2020-12-31 | $-91 |
| 2020-09-30 | $847 |
| 2020-06-30 | $314 |
| 2020-03-31 | $713 |
| 2019-12-31 | $208 |
| 2019-09-30 | $-106 |
| 2019-06-30 | $1,434 |
| 2019-03-31 | $673 |
| 2018-12-31 | $80 |
| 2018-09-30 | $489 |
| 2018-06-30 | $1,019 |
| 2018-03-31 | $1,114 |
| 2017-12-31 | $13,273 |
| 2017-09-30 | $1,026 |
| 2017-06-30 | $921 |
| 2017-03-31 | $1,153 |
| 2016-12-31 | $510 |
| 2016-09-30 | $1,009 |
| 2016-06-30 | $907 |
| 2016-03-31 | $837 |
| 2015-12-31 | $543 |
| 2015-09-30 | $764 |
| 2015-06-30 | $1,225 |
| 2015-03-31 | $1,255 |
| 2014-12-31 | $182 |
| 2014-09-30 | $2,061 |
| 2014-06-30 | $1,300 |
| 2014-03-31 | $697 |
| 2013-12-31 | $-769 |
| 2013-09-30 | $685 |
| 2013-06-30 | $960 |
| 2013-03-31 | $764 |
| 2012-12-31 | $533 |
| 2012-09-30 | $966 |
| 2012-06-30 | $627 |
| 2012-03-31 | $1,135 |
| 2011-12-31 | $100 |
| 2011-09-30 | $909 |
| 2011-06-30 | $646 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |